Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
Exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Protocol ID
INFORM2 NivEnt
Disease (Sub Disease)
CNS Tumour
Solid Tumour
Diagnosis Stage
Recurrent/ refractory
Location
NSW, VIC, WA
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
University Hospital Heidelberg
Collaborators
German Cancer Research Center
Trial Status
Open
Sites
Perth Children's Hospital
Sydney Children's Hospital
Royal Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
6 Years to 21 Years
International registry ID's
NCT03838042
Back to Registry
Study Title Exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Protocol ID INFORM2 NivEnt
Disease (Sub Disease) CNS Tumour
Solid Tumour
Diagnosis Stage Recurrent/ refractory
Location NSW / VIC / WA
Sponsor Australian and New Zealand Children's Haematology Oncology Group/ University Hospital Heidelberg
Collaborators German Cancer Research Center
Links https://clinicaltrials.gov/ct2/show/NCT03838042
Trial Status Open
Trial Open Date 26/07/2019
Sites Perth Children's Hospital / Sydney Children's Hospital / Royal Children's Hospital
Study Type Treatment
Phase Phase 1/2
Age Eligibility 6 Years to 21 Years
International registry ID's NCT03838042